CD4 and COVID-19: In conclusion, considering that point-of-care tests for assessing total CD3+ and CD3+CD4+ T-lymphocyte (and by subtraction CD3+CD8+ T-lymphocyte) absolute counts are already available, the TLSI could represent a useful tool for rapid and accurate mortality risk stratification in COVID-19 patients on hospital admission.